In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Agios Pharmaceuticals Inc (NASDAQ: AGIO) closed at $38.8 in the last session, up 1.57% from day before closing price of $38.2. In other words, the price has increased by $1.57 from its previous closing price. On the day, 0.72 million shares were traded. AGIO stock price reached its highest trading level at $39.685 during the session, while it also had its lowest trading level at $37.75.
Ratios:
We take a closer look at AGIO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 14.04 and its Current Ratio is at 14.48. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 24, 2025, initiated with a Buy rating and assigned the stock a target price of $58.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 08 ’25 when Goff Brian sold 11,085 shares for $36.67 per share. The transaction valued at 406,487 led to the insider holds 123,528 shares of the business.
Goff Brian bought 11,085 shares of AGIO for $410,810 on Aug 08 ’25. On Jul 10 ’25, another insider, Scadden David, who serves as the Director of the company, sold 1,400 shares for $40.00 each. As a result, the insider received 56,000 and left with 17,603 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGIO now has a Market Capitalization of 2254338048 and an Enterprise Value of 1364161920. As of this moment, Agios’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.51. For the stock, the TTM Price-to-Sale (P/S) ratio is 55.14 while its Price-to-Book (P/B) ratio in mrq is 1.64. Its current Enterprise Value per Revenue stands at 33.374 whereas that against EBITDA is -2.99.
Stock Price History:
The Beta on a monthly basis for AGIO is 0.87, which has changed by -0.16684562 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, AGIO has reached a high of $62.58, while it has fallen to a 52-week low of $23.42. The 50-Day Moving Average of the stock is 5.53%, while the 200-Day Moving Average is calculated to be 6.85%.
Shares Statistics:
According to the various share statistics, AGIO traded on average about 743.00K shares per day over the past 3-months and 516250 shares per day over the past 10 days. A total of 58.04M shares are outstanding, with a floating share count of 54.39M. Insiders hold about 6.39% of the company’s shares, while institutions hold 105.57% stake in the company. Shares short for AGIO as of 1753920000 were 4101620 with a Short Ratio of 5.52, compared to 1751241600 on 3780761. Therefore, it implies a Short% of Shares Outstanding of 4101620 and a Short% of Float of 7.1100004.
Earnings Estimates
The dynamic stock of Agios Pharmaceuticals Inc (AGIO) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$1.96, with high estimates of -$1.75 and low estimates of -$2.2.
Analysts are recommending an EPS of between -$6.99 and -$7.65 for the fiscal current year, implying an average EPS of -$7.38. EPS for the following year is -$7.06, with 7.0 analysts recommending between -$5.85 and -$9.34.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $10.49M. It ranges from a high estimate of $12.5M to a low estimate of $9M. As of the current estimate, Agios Pharmaceuticals Inc’s year-ago sales were $8.96MFor the next quarter, 8 analysts are estimating revenue of $14.14M. There is a high estimate of $15.9M for the next quarter, whereas the lowest estimate is $11.8M.
A total of 8 analysts have provided revenue estimates for AGIO’s current fiscal year. The highest revenue estimate was $47.9M, while the lowest revenue estimate was $42.8M, resulting in an average revenue estimate of $45.85M. In the same quarter a year ago, actual revenue was $36.5MBased on 8 analysts’ estimates, the company’s revenue will be $115.63M in the next fiscal year. The high estimate is $161.76M and the low estimate is $87.72M.
